Calliditas Total Liab vs Accounts Payable Analysis

CALT Stock

USD 20.64 0.51 2.53%

Calliditas Therapeutics financial indicator trend analysis is way more than just evaluating Calliditas Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Calliditas Therapeutics is a good investment. Please check the relationship between Calliditas Therapeutics Total Liab and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Calliditas Therapeutics Total Liab account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.

The correlation between Calliditas Therapeutics' Total Liab and Accounts Payable is 0.78. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Calliditas Therapeutics, assuming nothing else is changed. The correlation between historical values of Calliditas Therapeutics' Total Liab and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Calliditas Therapeutics are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Total Liab i.e., Calliditas Therapeutics' Total Liab and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Total Liab

The total amount of all liabilities that a company has, including both short-term and long-term liabilities.

Accounts Payable

An accounting item on the balance sheet that represents Calliditas Therapeutics obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Calliditas Therapeutics are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Calliditas Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Calliditas Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.At this time, Calliditas Therapeutics' Selling General Administrative is comparatively stable compared to the past year. Tax Provision is likely to gain to about 19.7 M in 2024, whereas Enterprise Value Over EBITDA is likely to drop (39.73) in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	7.1M	12.5M	73.2M	76.9M
Depreciation And Amortization	1K	12.9M	16.6M	17.4M

Interest Expense Depreciation And Amortization

Calliditas Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Net Tangible Assets	Current Deferred Revenue
Total Assets		0.51	0.79	0.81	0.76	-0.58	-0.88	0.92	0.98	0.89	0.59	0.98	0.78	0.97	0.83	0.91	0.47	0.99	0.75	0.75	0.99	0.99	0.82	0.68	0.7	0.43
Other Current Liab	0.51		0.86	0.19	0.83	0.2	-0.8	0.42	0.42	0.74	-0.18	0.42	0.83	0.44	0.48	0.62	1.0	0.5	0.87	0.85	0.48	0.55	0.68	0.87	0.29	-0.09
Total Current Liabilities	0.79	0.86		0.42	0.94	-0.02	-0.97	0.81	0.71	0.92	0.32	0.71	0.98	0.67	0.71	0.77	0.83	0.77	1.0	0.96	0.76	0.79	0.89	0.98	0.37	0.4
Total Stockholder Equity	0.81	0.19	0.42		0.44	-0.9	-0.56	0.61	0.89	0.64	0.52	0.89	0.43	0.85	0.58	0.85	0.17	0.83	0.36	0.42	0.84	0.8	0.54	0.25	0.93	0.18
Property Plant And Equipment Net	0.76	0.83	0.94	0.44		-0.05	-0.97	0.74	0.69	0.91	0.22	0.69	0.92	0.68	0.74	0.77	0.79	0.78	0.94	1.0	0.73	0.78	0.97	0.93	0.41	0.25
Net Debt	-0.58	0.2	-0.02	-0.9	-0.05		0.19	-0.38	-0.71	-0.28	-0.51	-0.71	-0.06	-0.68	-0.33	-0.61	0.22	-0.6	0.04	-0.02	-0.63	-0.57	-0.18	0.14	-0.85	-0.12
Retained Earnings	-0.88	-0.8	-0.97	-0.56	-0.97	0.19		-0.85	-0.81	-0.96	-0.36	-0.81	-0.95	-0.79	-0.78	-0.85	-0.76	-0.88	-0.96	-0.97	-0.85	-0.88	-0.95	-0.93	-0.49	-0.36
Accounts Payable	0.92	0.42	0.81	0.61	0.74	-0.38	-0.85		0.87	0.84	0.76	0.87	0.8	0.83	0.78	0.75	0.37	0.89	0.78	0.73	0.9	0.88	0.81	0.74	0.43	0.73
Cash	0.98	0.42	0.71	0.89	0.69	-0.71	-0.81	0.87		0.82	0.63	1.0	0.73	0.97	0.76	0.94	0.38	0.97	0.66	0.67	0.99	0.97	0.75	0.59	0.81	0.42
Non Current Assets Total	0.89	0.74	0.92	0.64	0.91	-0.28	-0.96	0.84	0.82		0.39	0.82	0.86	0.8	0.82	0.83	0.72	0.89	0.91	0.91	0.84	0.87	0.91	0.85	0.52	0.34
Non Currrent Assets Other	0.59	-0.18	0.32	0.52	0.22	-0.51	-0.36	0.76	0.63	0.39		0.63	0.35	0.51	0.5	0.4	-0.23	0.55	0.29	0.2	0.61	0.51	0.37	0.25	0.29	0.9
Cash And Short Term Investments	0.98	0.42	0.71	0.89	0.69	-0.71	-0.81	0.87	1.0	0.82	0.63		0.73	0.97	0.76	0.94	0.38	0.97	0.66	0.67	0.99	0.97	0.75	0.59	0.81	0.42
Net Receivables	0.78	0.83	0.98	0.43	0.92	-0.06	-0.95	0.8	0.73	0.86	0.35	0.73		0.68	0.67	0.8	0.78	0.76	0.98	0.94	0.78	0.79	0.88	0.97	0.42	0.42
Common Stock Total Equity	0.97	0.44	0.67	0.85	0.68	-0.68	-0.79	0.83	0.97	0.8	0.51	0.97	0.68		0.74	0.92	0.41	0.98	0.63	0.66	0.98	0.99	0.73	0.55	0.8	0.29
Common Stock Shares Outstanding	0.83	0.48	0.71	0.58	0.74	-0.33	-0.78	0.78	0.76	0.82	0.5	0.76	0.67	0.74		0.66	0.43	0.82	0.7	0.73	0.78	0.78	0.79	0.66	0.43	0.37
Capital Surpluse	0.91	0.62	0.77	0.85	0.77	-0.61	-0.85	0.75	0.94	0.83	0.4	0.94	0.8	0.92	0.66		0.58	0.92	0.73	0.76	0.94	0.94	0.78	0.66	0.87	0.21
Other Current Assets	0.47	1.0	0.83	0.17	0.79	0.22	-0.76	0.37	0.38	0.72	-0.23	0.38	0.78	0.41	0.43	0.58		0.46	0.84	0.81	0.44	0.52	0.63	0.83	0.26	-0.13
Other Stockholder Equity	0.99	0.5	0.77	0.83	0.78	-0.6	-0.88	0.89	0.97	0.89	0.55	0.97	0.76	0.98	0.82	0.92	0.46		0.73	0.76	0.98	0.99	0.84	0.66	0.73	0.38
Total Liab	0.75	0.87	1.0	0.36	0.94	0.04	-0.96	0.78	0.66	0.91	0.29	0.66	0.98	0.63	0.7	0.73	0.84	0.73		0.96	0.72	0.75	0.89	0.99	0.31	0.39
Property Plant And Equipment Gross	0.75	0.85	0.96	0.42	1.0	-0.02	-0.97	0.73	0.67	0.91	0.2	0.67	0.94	0.66	0.73	0.76	0.81	0.76	0.96		0.72	0.77	0.96	0.95	0.39	0.25
Total Current Assets	0.99	0.48	0.76	0.84	0.73	-0.63	-0.85	0.9	0.99	0.84	0.61	0.99	0.78	0.98	0.78	0.94	0.44	0.98	0.72	0.72		0.99	0.78	0.65	0.77	0.43
Common Stock	0.99	0.55	0.79	0.8	0.78	-0.57	-0.88	0.88	0.97	0.87	0.51	0.97	0.79	0.99	0.78	0.94	0.52	0.99	0.75	0.77	0.99		0.81	0.68	0.74	0.35
Property Plant Equipment	0.82	0.68	0.89	0.54	0.97	-0.18	-0.95	0.81	0.75	0.91	0.37	0.75	0.88	0.73	0.79	0.78	0.63	0.84	0.89	0.96	0.78	0.81		0.86	0.45	0.35
Short Long Term Debt Total	0.68	0.87	0.98	0.25	0.93	0.14	-0.93	0.74	0.59	0.85	0.25	0.59	0.97	0.55	0.66	0.66	0.83	0.66	0.99	0.95	0.65	0.68	0.86		0.22	0.4
Net Tangible Assets	0.7	0.29	0.37	0.93	0.41	-0.85	-0.49	0.43	0.81	0.52	0.29	0.81	0.42	0.8	0.43	0.87	0.26	0.73	0.31	0.39	0.77	0.74	0.45	0.22		-0.05
Current Deferred Revenue	0.43	-0.09	0.4	0.18	0.25	-0.12	-0.36	0.73	0.42	0.34	0.9	0.42	0.42	0.29	0.37	0.21	-0.13	0.38	0.39	0.25	0.43	0.35	0.35	0.4	-0.05

Click cells to compare fundamentals

Calliditas Therapeutics Account Relationship Matchups

Calliditas Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	845.2M	1.5B	1.5B	2.0B	1.9B	1.0B
Other Current Liab	25.6M	51.8M	13.9M	18.0M	287.9M	302.3M
Total Current Liabilities	53.4M	105.6M	135.4M	325.2M	407.1M	427.5M
Total Stockholder Equity	788.1M	1.2B	1.0B	766.3M	334.8M	582.2M
Property Plant And Equipment Net	6.1M	5.4M	39.6M	31.9M	54.2M	57.0M
Net Debt	(747.5M)	(991.5M)	(742.3M)	(520.3M)	5.4M	5.7M
Retained Earnings	(488.1M)	(918.6M)	(1.5B)	(1.8B)	(2.3B)	(2.2B)
Accounts Payable	24.4M	53.8M	68.0M	160.4M	100.6M	55.2M
Cash	753.5M	996.3M	955.5M	1.2B	973.7M	694.4M
Non Current Assets Total	24.1M	469.6M	447.1M	540.8M	625.4M	656.7M
Cash And Short Term Investments	753.5M	996.3M	955.5M	1.2B	973.7M	694.4M
Common Stock Total Equity	667K	1.4M	1.5M	2.0M	2.3M	1.2M
Common Stock Shares Outstanding	36.9M	44.9M	50.8M	53.0M	53.7M	42.4M
Liabilities And Stockholders Equity	845.2M	1.5B	1.5B	2.0B	1.9B	1.0B
Other Current Assets	1.6M	2.3M	22.8M	1K	92.8M	97.4M
Other Stockholder Equity	1.3B	2.1B	2.5B	2.6B	2.6B	1.6B
Total Liab	57.1M	250.2M	451.6M	1.2B	1.6B	1.6B
Property Plant And Equipment Gross	6.1M	5.4M	39.6M	35.6M	62.3M	65.5M
Total Current Assets	821.1M	1.0B	1.0B	1.4B	1.3B	772.7M
Accumulated Other Comprehensive Income	(45K)	(6.1M)	(27.0M)	9.3M	(5.2M)	(5.0M)
Common Stock	1.5M	2.0M	2.1M	2.4M	2.7M	1.6M
Property Plant Equipment	6.1M	5.4M	39.6M	31.9M	36.7M	38.5M
Net Tangible Assets	772.0M	749.1M	608.9M	282.4M	324.8M	479.2M
Other Assets	1.9M	600K	8.1M	(1K)	1.0	0.95
Non Current Liabilities Total	3.8M	144.5M	316.2M	861.5M	1.2B	1.2B
Net Invested Capital	788.1M	1.2B	1.2B	1.5B	1.3B	1.0B
Net Working Capital	767.8M	931.2M	877.3M	1.1B	868.0M	814.3M
Capital Stock	1.5M	2.0M	2.1M	2.4M	2.7M	2.2M

Pair Trading with Calliditas Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Calliditas Stock

0.61

BMY

Bristol Myers Squibb

Pair Corr

Moving against Calliditas Stock

0.5

ELYM

Eliem Therapeutics Trending

Pair Corr

The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.

The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Calliditas Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Calliditas Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Calliditas Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Calliditas Therapeutics Stock:

How To Invest In Calliditas

Details

Is Calliditas Stock a good investment?

Details

What is Calliditas Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Calliditas Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Complementary Tools for Calliditas Stock analysis

When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments

Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.60)

Revenue Per Share

44.972

Quarterly Revenue Growth

0.052

Return On Assets

(0.13)

Return On Equity

(0.85)

The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Calliditas Total Liab vs Accounts Payable Analysis

Total Liab vs Accounts Payable

Total Liab vs Accounts Payable Correlation Analysis

Correlation Coefficient

Total Liab

Accounts Payable

Calliditas Therapeutics fundamental ratios Correlations

Calliditas Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Calliditas Therapeutics fundamental ratios Accounts

Pair Trading with Calliditas Therapeutics

Moving together with Calliditas Stock

Moving against Calliditas Stock

Complementary Tools for Calliditas Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Assets	+ 1.0	Other Current Liab
Total Liab	+ 1.0	Total Current Liabilities
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Other Stockholder Equity	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets

Property Plant And Equipment Gross	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Property Plant And Equipment Net
Retained Earnings	- 0.97	Total Current Liabilities
Total Liab	- 0.96	Retained Earnings
Non Current Assets Total	- 0.96	Retained Earnings
Property Plant Equipment	- 0.95	Retained Earnings